Subscribe
shutterstock_1492661771_ricochet64-1
ricochet64 / Shutterstock.com
11 May 2021Big PharmaMuireann Bolger

Mylan fails to void MSD diabetes treatment patent at PTAB

MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Acorda and AstraZeneca claim victory over Mylan
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.
Americas
AbbVie and Mylan agree Humira licensing deal
18 July 2018   US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Acorda and AstraZeneca claim victory over Mylan
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.
Americas
AbbVie and Mylan agree Humira licensing deal
18 July 2018   US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

More on this story

Americas
Acorda and AstraZeneca claim victory over Mylan
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.
Americas
AbbVie and Mylan agree Humira licensing deal
18 July 2018   US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility